Dr. Reddy's Q1 FY26 Revenues Up 11% YoY Amidst US Generics Decline; Strategic Pipeline Progress
This announcement is an earnings call transcript, providing comprehensive insights into the company's financial performance across all segments, strategic initiatives, pipeline progress, and regulatory compliance. It includes forward-looking statements and management commentary, which are critical for investor decision-making and understanding the company's future trajectory and operational health.
The company reported mixed financial results with strong revenue growth and EBITDA margin ahead of aspiration, but faced a significant decline in US generics due to Lenalidomide price erosion. Strategic initiatives in biosimilars and consumer healthcare are progressing well, and the company provided a clear outlook on key pipeline products like Semaglutide and Abatacept. While regulatory observations were noted, management expressed confidence in positive resolutions. The overall outlook balances current challenges with future growth drivers and cost management efforts.
* Consolidated revenues for Q1 FY26 stood at ₹8,545 crore ($997 million), an increase of 11% year-on-year (YoY), remaining flat sequentially. This growth was driven by steady performance across most markets, excluding the US generics business. * EBITDA was ₹2,278 crore ($266 million), up 5% YoY, with an EBITDA margin of 26.7%, exceeding the aspiration of 25%. Profit after tax was ₹1,419 crore ($166 million), a 2% YoY growth, representing 16.6% of revenues. Diluted EPS was ₹17.04. * Gross profit margin decreased by 350 basis points YoY to 56.9%, primarily due to price erosion in generics, particularly Lenalidomide, and lower operating leverage. SG&A expenses increased by 13% YoY to ₹2,565 crore ($299 million), driven by strategic investments in consumer healthcare businesses (NRT and Nestlé JV). * R&D spend was ₹624 crore ($73 million), representing 7.3% of sales. The company expects R&D investment to be in the range of 7-7.5% of sales for the full fiscal year and a normalized Effective Tax Rate (ETR) of around 25%. * The company closed the quarter with a net cash surplus of ₹2,922 crore ($341 million). * Business Segment Performance: * North America Generics revenues declined 17% YoY to $400 million (₹3,429.6 crore) due to price erosion in select products, mainly Lenalidomide, and timing of customer procurement. The company expects a pick-up in new product launches to support recovery. * European Generics revenues grew 124% YoY to €131 million (approx ₹1,123.1 crore), fueled by contributions from the acquired Nicotine Replacement Therapy (NRT) portfolio and new product launches. * Emerging Markets reported revenues of ₹1,404 crore, up 10% YoY, with Russia business growing 17% YoY in constant currency terms. * India business revenues were ₹1,471 crore, delivering 11% YoY growth, driven by new products and pricing. Dr. Reddy's remains the 10th largest player in the Indian Pharmaceutical Market. * PSAI business revenues were $95 million (₹814.5 crore), up 4% YoY, with momentum expected to pick up for double-digit growth for the fiscal year. * Strategic Highlights & Outlook: * The biosimilars business gained momentum with a strategic collaboration with Alvotech for pembrolizumab, a biosimilar to Keytruda®. * Integration of the acquired NRT business is progressing, with plans to onboard additional markets like Canada and Australia. * Management expects Semaglutide approval between end of October to beginning of November 2025, with potential launch in January 2026 at loss of exclusivity. Canada launch could be earlier. The company plans to have about 10 million pens available in calendar 2026 and 12 million pens in FY27 from its partner. * Phase III trials for the biosimilar Abatacept are progressing, with readout expected in November 2025 and BLA submission planned for market formation in December 2026 or January 2027. * Regulatory Updates: * USFDA inspected the Middleburgh API facility in New York, issuing a Form 483 with two observations, and subsequently classified the site as VAI (Voluntary Action Indicated). * A GMP inspection at CTO-5 API facility in Miryalaguda, Telangana, resulted in a Form 483 with two observations, with responses submitted. * A GMP and Pre-Approval Inspection at FTO-11 formulations facility in Srikakulam, Andhra Pradesh, resulted in a Form 483 with seven observations. Management expects a VAI classification for this site. * Management Commentary: MV Narasimham stated that gross margins for FY26 would be at similar levels, with future improvements expected upon Semaglutide launch. SG&A costs are expected to be in the 28-29% range for the full fiscal year. Erez Israeli noted the potential for 500-600 basis points in discretionary cost savings, depending on growth and investment needs, aiming to maintain a 25% EBITDA margin and double-digit growth. Aurigene Pharma Services (CDMO) is targeted to reach $100 million (₹857.4 crore) in sales for FY26 and $250-300 million (₹2,143.5 crore - ₹2,572.2 crore) by 2030.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.